Cancer pain that persists around the clock is managed with two coordinated opioid components: a scheduled long-acting formulation that maintains a steady baseline, and a short-acting rescue dose for pain that breaks through that baseline. The dose conversion question asks you to take the total morphine actually consumed over the previous 24 hours and redistribute it entirely into the scheduled extended-release regimen.
In this patient, the scheduled dose is 30 mg of extended-release morphine every 12 hours, which means 60 mg over 24 hours. He also required 4 breakthrough doses of immediate-release morphine at 10 mg each, adding 40 mg. The total opioid used in one day is therefore 100 mg.
The new order converts that total 24-hour requirement into two equal extended-release doses, so each dose is 100 mg divided by 2, or 50 mg every 12 hours. This approach is consistent with the principle that around-the-clock dosing with a rescue option is the standard strategy for persistent cancer pain, because it prevents the peaks and troughs that occur when pain is treated only as needed.
When adjusting opioid regimens, the immediate-release and extended-release forms of the same opioid are considered equivalent milligram for milligram. Morphine immediate-release and morphine extended-release differ only in their release kinetics, not in their opioid content. Opioid rotation to a different drug would require a conversion factor, but no rotation occurs here, so the arithmetic remains direct addition.
| Component | Dose | Frequency | 24-hour total |
|---|---|---|---|
| Extended-release morphine | 30 mg | every 12 hours | 60 mg |
| Immediate-release morphine | 10 mg | 4 breakthrough doses | 40 mg |
| Total 24-hour morphine | 100 mg | ||
| New extended-release dose | 50 mg | every 12 hours | 100 mg |
Watch out! A common error is to add only the breakthrough doses to one scheduled dose, yielding 30 + 40 = 70 mg. That answer fails to account for the fact that the patient took two scheduled doses during the 24-hour period. The calculation must begin with the total daily scheduled amount, not a single dose.
Key point! Breakthrough dose requirements are a clinical signal that the baseline opioid is insufficient. When a patient repeatedly needs rescue doses, the scheduled dose should be increased based on the total opioid consumed, rather than simply continuing to add more rescue doses.
In cancer pain management, the goal of dose titration is to find the lowest scheduled dose that keeps pain controlled with minimal rescue use. The frequency of breakthrough dosing guides upward titration. The total daily opioid requirement is the sum of scheduled and rescue doses, and converting that total into the extended-release formulation maintains stable serum opioid concentrations.
For a patient with bone metastases from prostate cancer, nociceptive pain from tumor invasion of the periosteum and surrounding structures often produces continuous aching pain punctuated by incident or movement-related flares. This pattern supports a long-acting baseline opioid with a short-acting agent available for predictable or unpredictable exacerbations.
The immediate-release morphine starting dose in opioid-naive cancer patients is typically 5 mg every 4 hours, while patients already on weak opioids may start at 10 mg [1]. This patient, however, is already established on morphine, so the question is not about initiating therapy but about recalculating an existing regimen based on actual consumption.
Dose standardization matters when comparing opioids across studies or when transitioning between formulations. Morphine milligram equivalent calculators exist to harmonize comparisons among different opioids, but within a single opioid such as morphine, the conversion factor is 1, meaning no adjustment is needed when moving between immediate-release and extended-release forms of the same drug .
Systematic reviews comparing controlled-release oxycodone and sustained-release morphine for cancer pain titration have examined efficacy and safety, but the arithmetic of dose calculation remains independent of which long-acting opioid is chosen . The principle of summing total daily opioid use applies regardless of the specific agent.
In palliative care, opioid doses are adjusted to changing requirements, and inadequate analgesia often stems from insufficient knowledge about dose adjustment rather than from the opioid itself . The calculation in this scenario reflects that core competency: recognizing when the current regimen is inadequate and converting the actual opioid requirement into a revised scheduled dose.
The correct new extended-release morphine dose is 50 mg every 12 hours, because it delivers the full 100 mg of morphine the patient required over the previous 24 hours in two equal scheduled doses.
For persistent cancer pain, use around-the-clock (ATC) dosing with a scheduled long-acting opioid plus a short-acting rescue dose for breakthrough pain. The goal is to maintain a steady baseline and avoid peaks and troughs.
To convert to a new scheduled regimen, add all morphine consumed in the past 24 hours: scheduled 30 mg × 2 = 60 mg plus breakthrough 10 mg × 4 = 40 mg, totaling 100 mg. Divide by 2 for every-12-hour dosing: each new ER dose is 50 mg.
When converting between immediate-release and extended-release forms of the same opioid, the conversion is milligram-for-milligram equivalent. No adjustment factor is needed unless rotating to a different opioid.
Do not confuse the total 24-hour requirement with the per-dose amount. Always divide the total by the number of scheduled doses per day. Reassess pain control and monitor for opioid toxicity after any dose adjustment.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.